Oral bisphosphonates do not increase the risk of severe upper gastrointestinal complications: a nested case–control study

BMC Gastroenterology

Giovanni Corrao⁷  Giampiero Mazzaglia^1,10  Tommaso Staniscia¹  Annarita Vestri²  Rosaria Gesuita⁵  Dario Gregori⁶  Alberto Vaccheri⁸  Achille P Caputi³  Francesco Cipriani^1,10  Francesco Lapi^1,11  Luca Cavalieri D’Oro⁹  Gianluca Della Vedova⁴  Lorenza Scotti⁷  Arianna Ghirardi⁷ 

[1] Department of Medicine and Aging, University “G. d’Annunzio”, Chieti-Pescara, Italy;Department of Public Health and Infectious Diseases, University “La Sapienza”, Rome, Italy;Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy;Department of Informatics, Systems and Communications, University of Milano-Bicocca, Milan, Italy;Center of Epidemiology, Biostatistics, and Medical Information Technology, Polytechnic University of Marche, Ancona, Italy;Department of Public Health and Microbiology, University of Turin, Turin, Italy;Department of Statistics and Quantitative Methods, Unit of Biostatistics and Epidemiology, University of Milano-Bicocca, Via Bicocca degli Arcimboldi 8, 20126 Milan, Italy;Regional Centre for Drug Evaluation and Information (CREVIF), Department of Pharmacology, University of Bologna, Bologna, Italy;Operative Unit of Epidemiology, Local Health Unit of Monza and Brianza, Monza, Italy;Department of Epidemiology, Regional Agency for Healthcare Services of Tuscany, Florence, Italy;Centre for Clinical Epidemiology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada

关键词: Upper gastrointestinal complications;    Healthcare utilization database;    Drug safety;    Bisphosphonates;   

Others  :  856755
DOI  :  10.1186/1471-230X-14-5

 received in 2012-10-08, accepted in 2013-12-18,  发布年份 2014

【 摘 要 】

Background

Data on the effect of oral bisphosphonates (BPs) on risk of upper gastrointestinal complications (UGIC) are conflicting. We conducted a large population-based study from a network of Italian healthcare utilization databases aimed to assess the UGIC risk associated with use of BPs in the setting of secondary prevention of osteoporotic fractures.

Methods

A nested case–control study was carried out within a cohort of 68,970 patients aged 45 years or older, who have been hospitalized for osteoporotic fracture from 2003 until 2005. Cases were the 804 patients who experienced hospitalization for UGIC until 2007. Up to 20 controls were randomly selected for each case. Conditional logistic regression model was used to estimate odds ratio (OR) associated with current and past use of BPs (i.e. for drug dispensation within 30 days and over 31 days prior the outcome onset, respectively) after adjusting for several covariates.

Results

Compared with patients who did not use BPs, current and past users had OR (and 95% confidence interval) of 0.86 (0.60 to 1.22) and 1.07 (0.80 to 1.44) respectively. There was no difference in the ORs estimated according with BPs type (alendronate or risedronate) and regimen (daily or weekly), nor with co-therapies and comorbidities.

Conclusions

Further evidence that BPs dispensed for secondary prevention of osteoporotic fractures are not associated with increased risk of severe gastrointestinal complications is supplied from this study. Further research is required to clarify the role BPs and other drugs of co-medication in inducing UGIC.

【 授权许可】

   
2014 Ghirardi et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]National Osteoporosis Foundation: Physicians’ Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 1999.
• [2]Scientific Advisory Board, Osteoporosis Society of Canada: Clinical practice guidelines for the diagnosis and management of osteoporosis. CMAJ 1996, 155:1113-1128.
• [3]Klotzbuecher CM, Ross PD, Landsman PB, et al.: Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000, 15:721-739.
• [4]Freedman KB, Kaplan FS, Bilker WB, et al.: Treatment of osteoporosis: are physicians missing an opportunity? J Bone Joint Surg Am 2000, 82:1063-1070.
• [5]Siris ES, Miller PD, Barrett-Connor E, et al.: Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women. JAMA 2001, 286:2815-2822.
• [6]Epstein S, Goodman GR: Improved strategies for diagnosis and treatment of osteoporosis. Menopause 1999, 6:242-250.
• [7]McClung MR: Therapy for fracture prevention. JAMA 1999, 282:687-689.
• [8]Melton LJ III, Thamer R, Ray NF, et al.: Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res 1997, 12:16-23.
• [9]Earnshaw SA, Cawte SA, Worley A, et al.: Colles’ fracture of the wrist as an indicator of underlying osteoporosis in post-menopausal women: a prospective study of bone mineral density and bone turnover rate. Osteoporos Int 1998, 8:53-60.
• [10]Seeley DG, Browner WS, Nevitt MC, et al.: Which fractures are associated with low appendicular bone mass in elderly women? Ann Intern Med 1991, 115:837-842.
• [11]Hajcsar EE, Hawker G, Bogoch ER: Investigation and treatment of osteoporosis in patients with fragility fractures. CMAJ 2000, 163:819-822.
• [12]Liberman UA, Weiss SR, Broll J, et al.: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995, 333:1437-1443.
• [13]Black DM, Cummings SR, Karpf DB, et al.: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348:1535-1541.
• [14]Cummings SR, Black DM, Thompson DE, et al.: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998, 280:2077-2082.
• [15]Pols HA, Felsenberg D, Hanley DA, et al.: Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999, 9:461-468.
• [16]Harris ST, Watts NB, Genant HK, et al.: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999, 282:1344-1352.
• [17]Reginster J, Minne HW, Sorensen OH, et al.: Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000, 11:83-91.
• [18]McClung MR, Geusens P, Miller PD, et al.: Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001, 344:333-340.
• [19]Tonino RP, Meunier PJ, Emkey R, et al.: Phase III Osteoporosis Treatment Study Group. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 2000, 85:3109-3115.
• [20]Mortensen L, Charles P, Bekker PJ, et al.: Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 1998, 83:396-402.
• [21]Wallach S, Cohen S, Reid DM, et al.: Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000, 67:277-285.
• [22]Graham DY: What the gastroenterologists should know about the gastrointestinal safety profiles of bisphosphonates. Dig Dis Sci 2002, 47:1665-1678.
• [23]De Groen PC, Lubbe DF, Hirsch LJ, et al.: Esophagitis associated with the use of alendronate. N Engl J Med 1996, 335:1016-1021.
• [24]Van Staa T, Abenhaim L, Cooper C: Upper gastrointestinal adverse events and cyclical etidronate. Am J Med 1997, 103:462-467.
• [25]Donahue JG, Chan KA, Andrade SE, et al.: Gastric and duodenal safety of daily alendronate. Arch Intern Med 2002, 162:936-942.
• [26]Miller RG, Bolognese M, Worley K, et al.: Incidence of gastrointestinal events among bisphosphonate patients in an observational setting. Am J Manag Care 2004, 10:S207-S215.
• [27]Etminan M, Lévesque L, Fitzgerald JM, et al.: Risk of upper gastrointestinal bleeding with oral bisphosphonates and non steroidal anti-inflammatory drugs: a case–control study. Aliment Pharmacol Ther 2009, 29:1188-1192.
• [28]Cadarette SM, Katz JN, Brookhart MA, et al.: Comparative gastrointestinal safety of weekly oral bisphosphonates. Osteoporos Int 2009, 20:1735-1747.
• [29]Miyake K, Kusunoki M, Shinji Y, et al.: Bisphosphonate increases risk of gastroduodenal ulcer in rheumatoid arthritis patients on long-term nonsteroidal antiinflammatory drug therapy. J Gastroenterol 2009, 44:113-120.
• [30]Cryer B, Bauer DC: Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc 2002, 77:1031-1043.
• [31]MacLean C, Newberry S, Maglione M, et al.: Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008, 148:197-213.
• [32]Lapi F, Cipriani F, Caputi AP, on behalf of the Bisphosphonates Efficacy-Safety Tradeoff (BEST) study group, et al.: Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures. Osteoporos Int 2013, 24:697-705.
• [33]Federal Information Processing Standards. Secure Hash Standard (SHS). 2000, PUB 180-184. http://csrc.nist.gov/publications/fips/fips180-4/fips-180-4.pdf webcite
• [34]Charlson ME, Charlson RE, Peterson JC, et al.: The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol 2008, 61:1234-1240.
• [35]Coloma PM, Schuemie MJ, Trifirò G, et al.: Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf 2011, 20:1-11.
• [36]Bauer DC, Black D, Ensrud K, et al.: Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 2000, 160:517-525.
• [37]Taggart H, Bolognese MA, Lindsay R, et al.: Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc 2002, 77:262-270.
• [38]Dalton SO, Johansen C, Mellemkjaer L, Nørgård B, Sørensen HT, Olsen JH: Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Int Med 2003, 163:59-64.
• [39]Zullo A, Hassan C, Campo SM, Morini S: Bleeding peptic ulcer in the elderly: risk factors and prevention strategies. Drugs Aging 2007, 24:815-828.
• [40]Tata LJ, Fortun PJ, Hubbard RB, et al.: Does concurrent prescription of selective serotonin reuptake inhibitors and non- steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding? Aliment Pharmacol Ther 2005, 22:175-181.
• [41]Hernàndez-Diaz S, Garcìa Rodriguez LA: Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Int Med 2000, 160:2093-2099.
• [42]Ramakrishnan K, Salinas RC: Peptic ulcer disease. Am Fam Physician 2007, 76:1005-1012.
• [43]Udd M, Miettinen P, Palmu A, et al.: Analysis of the risk factors and their combinations in acute gastroduodenal ulcer bleeding: a case–control study. Scand J Gastroenterol 2007, 42:1395-1403.
• [44]García Rodríguez LA, Lin KJ, Hernández-Díaz S, Johansson S: Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation 2011, 123:1108-1115.
• [45]Schelleman H, Bilker WB, Brensinger CM, Wan F, Yang YX, Hennessy S: Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk. Am J Med 2010, 123:151-157.
• [46]García Rodríguez LA, Cattaruzzi C, Troncon MG: Risk of hospitalization for upper gastrointestinal bleeding associated with ketorolac, other NSAIDs, calcium antagonists and other antihypertensive drugs. Arch Int Med 1998, 158:33-39.
• [47]Laporte JR, Ibanez L, Vidal X, Vendrell L, Leone R: Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf 2004, 27:411-420.
• [48]Strom BL: Overview of automated databases in pharmacoepidemiology. In Pharmacoepidemiology. 3rd edition. Edited by Strom BL. Chichester, UK: Wiley; 2000:219-222.
• [49]Tamim H, Monfared AA, LeLorier J: Application of lag-time into exposure definitions to control for protopathic bias. Pharmacoepidemiol Drug Saf 2007, 16:250-258.